Feliqs
Tokyo, Japan· Est.
Clinical-stage ophthalmology company developing innovative therapies for retinopathy of prematurity and age-related macular degeneration.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Clinical-stage ophthalmology company developing innovative therapies for retinopathy of prematurity and age-related macular degeneration.
OncologyImmunology
Technology Platform
Antibody-based therapeutic platform for ocular diseases, though specific technology details are not explicitly stated on their website.
Opportunities
Addressing significant unmet needs in both neonatal ophthalmology (ROP) and age-related eye diseases (geographic atrophy) with novel therapeutic approaches in growing markets.
Risk Factors
Early clinical stage with lead candidate only in Phase 1b, competing in crowded ophthalmology space against established players, and dependence on successful cross-border development between Japan and U.S.
Competitive Landscape
Competes in ophthalmology with companies like Regeneron (Eylea), Roche (Lucentis), and newer entrants in geographic atrophy; differentiation through focus on neonatal conditions and dual Japan-U.S. development strategy.